Is STOK or STRO more undervalued in 2026?

CirclFi compares Stoke Therapeutics, Inc. (STOK) and Sutro Biopharma, Inc. (STRO) using 13 institutional-grade valuation models. STOK has a Quality of Company score of 6.2/10 while STRO scores 5.6/10.

Which is a better buy — STOK or STRO?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do STOK and STRO valuations compare?

STOK at $31.61 and STRO at $29.63 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

STOK vs STRO Valuation Comparison 2026 — Intrinsic Value Analysis

STOK

Biotechnology

Stoke Therapeutics, Inc.

Quality

6.2

out of 10

Value Trap

SAFE

Price

$31.61

Last close

Models

13/13

Active

STRO

Biotechnology

Sutro Biopharma, Inc.

Quality

5.6

out of 10

Value Trap

SAFE

Price

$29.63

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	STOK Fair Value	STOK Upside	STRO Fair Value	STRO Upside
Bayesian DCF	Intrinsic	$11.28	-64.3%	$7.89	-73.4%
Earnings Power Value	Intrinsic	$6.33	-81.0%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$6.71	-78.8%	$4.73	-84.0%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for STOK vs STRO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

STOK vs STRO — Which Stock Is More Undervalued?

STOK scores higher with a 6.2/10 quality rating vs STRO's 5.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Stoke Therapeutics, Inc. (STOK) and Sutro Biopharma, Inc. (STRO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

STOK currently trades at $31.61 with a QOC of 6.2/10, while STRO trades at $29.63 with a QOC of 5.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).